Update on pharmacologic therapy for pulmonary embolism

Prakash Harikrishnan, Chandrasekar Palaniswamy, Wilbert S. Aronow

Research output: Contribution to journalReview article

Abstract

Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume19
Issue number2
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Pulmonary Embolism
Anticoagulants
Warfarin
Heparin
Dalteparin
Enoxaparin
Low Molecular Weight Heparin
Venous Thromboembolism
Therapeutics
Pharmaceutical Preparations
Rivaroxaban

Keywords

  • apixaban
  • dabigatran
  • pulmonary embolism
  • rivaroxaban
  • warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Update on pharmacologic therapy for pulmonary embolism. / Harikrishnan, Prakash; Palaniswamy, Chandrasekar; Aronow, Wilbert S.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 19, No. 2, 01.03.2014, p. 159-169.

Research output: Contribution to journalReview article

Harikrishnan, Prakash ; Palaniswamy, Chandrasekar ; Aronow, Wilbert S. / Update on pharmacologic therapy for pulmonary embolism. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2014 ; Vol. 19, No. 2. pp. 159-169.
@article{bbf3b29434b3402b85cf98f7314bf279,
title = "Update on pharmacologic therapy for pulmonary embolism",
abstract = "Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.",
keywords = "apixaban, dabigatran, pulmonary embolism, rivaroxaban, warfarin",
author = "Prakash Harikrishnan and Chandrasekar Palaniswamy and Aronow, {Wilbert S.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1177/1074248413506612",
language = "English (US)",
volume = "19",
pages = "159--169",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Update on pharmacologic therapy for pulmonary embolism

AU - Harikrishnan, Prakash

AU - Palaniswamy, Chandrasekar

AU - Aronow, Wilbert S.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.

AB - Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.

KW - apixaban

KW - dabigatran

KW - pulmonary embolism

KW - rivaroxaban

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84894448506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894448506&partnerID=8YFLogxK

U2 - 10.1177/1074248413506612

DO - 10.1177/1074248413506612

M3 - Review article

C2 - 24177334

AN - SCOPUS:84894448506

VL - 19

SP - 159

EP - 169

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 2

ER -